Information Provided By:
Fly News Breaks for May 15, 2019
May 15, 2019 | 15:50 EDT
Wells Fargo analyst David Maris continues to be cautious on Teva (TEVA) and Mylan (MYL) following the price fixing lawsuit against generic companies, and said that the lack of criminal charges "does not take away the financial overhang of the suit." The analyst added that this suit may stop "opportunistic price increases in generics." He remains on the sidelines on both Teva and Mylan, both of which he has Market Perform ratings on.